BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31704874)

  • 21. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis.
    Kanyama M; Kuboki T; Kojima S; Fujisawa T; Hattori T; Takigawa M; Yamashita A
    J Orofac Pain; 2000; 14(1):20-30. PubMed ID: 11203734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
    Lubowicka E; Zbucka-Kretowska M; Sidorkiewicz I; Zajkowska M; Gacuta E; Puchnarewicz A; Chrostek L; Szmitkowski M; Ławicki S
    Pathol Oncol Res; 2020 Apr; 26(2):791-800. PubMed ID: 30820752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
    Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
    Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
    Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
    J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
    Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
    Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
    Pietruszewska W; Bojanowska-Poźniak K; Kobos J
    Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
    Zhou CY; Yao JF; Chen XD
    Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
    Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
    Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
    Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
    Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporospatial distribution of matrix metalloproteinase and tissue inhibitors of matrix metalloproteinases during murine secondary palate morphogenesis.
    Morris-Wiman J; Burch H; Basco E
    Anat Embryol (Berl); 2000 Aug; 202(2):129-41. PubMed ID: 10985432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix.
    Davidson B; Goldberg I; Liokumovich P; Kopolovic J; Gotlieb WH; Lerner-Geva L; Reder I; Ben-Baruch G; Reich R
    Int J Gynecol Pathol; 1998 Oct; 17(4):295-301. PubMed ID: 9785129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association analysis of genetic polymorphisms and expression levels of selected genes involved in extracellular matrix turnover and angiogenesis with the risk of age-related macular degeneration.
    Oszajca K; Szemraj M; Szemraj J; Jurowski P
    Ophthalmic Genet; 2018 Dec; 39(6):684-698. PubMed ID: 30289322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
    Bai SX; Wang YL; Qin L; Xiao ZJ; Herva R; Piao YS
    Reproduction; 2005 Jan; 129(1):103-13. PubMed ID: 15615902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinases and their endogenous inhibitors during the implantation period in the rat uterus.
    Hurst PR; Palmay RD
    Reprod Fertil Dev; 1999; 11(7-8):395-402. PubMed ID: 11101274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
    Baker EA; Leaper DJ
    Wound Repair Regen; 2000; 8(5):392-8. PubMed ID: 11115151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in gingival crevicular fluid during orthodontic tooth movement.
    Bildt MM; Bloemen M; Kuijpers-Jagtman AM; Von den Hoff JW
    Eur J Orthod; 2009 Oct; 31(5):529-35. PubMed ID: 19299245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
    Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
    Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.